Literature DB >> 10599785

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.

N R Miller1, M A Johnson, S R Paul, C A Girkin, J D Perry, M Endres, G L Krauss.   

Abstract

BACKGROUND: Vigabatrin is an antiepileptic drug that, although relatively well tolerated, is associated with visual field constriction and other visual disturbances of unclear origin.
METHODS: We performed a complete neuroophthalmologic examination and electrophysiologic studies on 39 patients receiving vigabatrin and on 11 control patients.
RESULTS: Nearly 50% of patients receiving vigabatrin had constricted visual fields compared with control patients. Some of the vigabatrin patients also had reduced visual acuity and abnormal color vision. In addition, most vigabatrin patients had abnormal electroretinographic results, the severity of which correlated strongly with the degree of visual field constriction.
CONCLUSIONS: Vigabatrin can cause electrophysiologic evidence of retinal dysfunction and clinically detectable disturbances of visual sensory function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10599785     DOI: 10.1212/wnl.53.9.2082

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.

Authors:  I F Comaish; C Gorman; N R Galloway
Journal:  BMJ       Date:  2000-05-20

2.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

3.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

4.  Are vigabatrin-associated visual field constrictions asymptomatic?

Authors:  T Schmidt; K Rüther; B Schmitz
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

5.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 6.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Neuropsychological and behavioral effects of antiepilepsy drugs.

Authors:  David W Loring; Susan Marino; Kimford J Meador
Journal:  Neuropsychol Rev       Date:  2007-10-18       Impact factor: 7.444

8.  Evaluating risks for vigabatrin treatment.

Authors:  Gregory L Krauss
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

9.  mTOR Inhibition Mitigates Molecular and Biochemical Alterations of Vigabatrin-Induced Visual Field Toxicity in Mice.

Authors:  Kara R Vogel; Garrett R Ainslie; Michelle A Schmidt; Jonathan P Wisor; K Michael Gibson
Journal:  Pediatr Neurol       Date:  2016-10-03       Impact factor: 3.372

10.  Vigabatrin and visual field defects in pediatric epilepsy patients.

Authors:  Su Jeong You; HyoSook Ahn; Tae-Sung Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.